Opportunity Information: Apply for CDC RFA GH13 1335
Apply for CDC RFA GH13 1335
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Strengthen capacity of the South African Governments Department of Health to provide quality and sustainable clinical care for HIV infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretrov" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on Feb 26, 2013 and posted on Feb 26, 2013.
- Applicants must submit their applications by Apr 15, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $50,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $5,000,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- ELIGIBILITY INFORMATION Eligible Applicants Eligible applicants that can apply for this funding opportunity are listed below Nonprofit with 501C3 IRS status (other than institution of higher education) Nonprofit without 501C3 IRS status (other than institution of higher education) For profit organizations (other than small business) Small, minority, and women owned businesses Universities Colleges Research institutions Hospitals Community based organizations Faith based organizations Federally recognized or state recognized American Indian/Alaska Native tribal governments American Indian/Alaska native tribally designated organizations Alaska Native health corporations Urban Indian health organizations Tribal epidemiology centers State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) Political subdivisions of States (in consultation with States) Non domestic (non U.S.) entity A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (CDC RFA GH13-1335) is a U.S. Centers for Disease Control and Prevention (CDC) cooperative agreement under PEPFAR, focused on strengthening the South African Department of Healths capacity to deliver high-quality, sustainable clinical care for people living with HIV, especially patients with complicated HIV disease and those requiring complex HIV/TB co-treatment and advanced antiretroviral management. A central emphasis is improving the systems and clinical expertise needed to manage second-line and third-line antiretroviral therapy and other advanced HIV treatment needs, in alignment with South Africas national strategic plans and broader partnership framework coordinated under the U.S. Global AIDS Coordinator.
Programmatically, the opportunity sits within CDCs typical approach of concentrating support in a small number of major areas per country and tailoring technical assistance to host-country priorities. The grant describes four broad priority areas that frame the work. First is primary prevention of HIV infection, including expansion of confidential counseling and testing that is connected to evidence-based behavior change interventions, along with strengthening efforts to prevent mother-to-child transmission. Second is improving care and treatment across HIV/AIDS, sexually transmitted infections, and opportunistic infections by upgrading STI management, expanding laboratory diagnostic capacity, and improving detection and treatment of opportunistic infections and other conditions that worsen outcomes for people with HIV, with tuberculosis highlighted as a key co-morbidity. This includes support for initiating and improving antiretroviral therapy programs and the clinical systems needed to sustain them. Third is building national capacity to collect, analyze, and use surveillance and program data to manage HIV/AIDS programs more effectively, including expansion of HIV/STI/TB surveillance and stronger laboratory support for surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety. Fourth is developing, validating, and evaluating public health programs so that prevention and treatment interventions for HIV, TB, and opportunistic infections can be better targeted and continuously improved based on evidence.
In practical terms, applicants are expected to work closely with the South African government and other partners in a collaborative model typical of a cooperative agreement, where CDC is substantially involved in guiding and supporting implementation. The overall intent is not just direct service delivery, but durable capacity building: strengthening clinical and program management systems, improving quality of care for complex cases, reinforcing lab and surveillance infrastructure, and ensuring that advanced HIV and HIV/TB treatment services (including second- and third-line ART) can be delivered reliably and at scale over time.
The opportunity was posted February 26, 2013, with an original and final closing date of April 15, 2013, and an archive date of May 15, 2013. CDC anticipated making 3 awards, with an estimated total funding amount of $50,000,000 and an award ceiling of $5,000,000; the award floor was listed as $0. There was no cost sharing or matching requirement. The activity category is health, the funding instrument is a cooperative agreement, and the CFDA number is 93.067 (Global AIDS).
Eligibility was broad and included U.S. and non-U.S. entities across nonprofit and for-profit sectors, universities and colleges, research institutions, hospitals, community- and faith-based organizations, tribal governments and tribally designated organizations, tribal epidemiology centers, and state and local governments (including U.S. territories and freely associated states). The announcement also allowed applications from bona fide agents of state or local governments, provided they submitted a legal binding agreement documenting that status. For access issues or administrative support, the CDC Procurement and Grants Office Technical Information Management Section (TIMS) was listed as the point of contact at 770-488-2700 or pgotim@cdc.gov.
Frequently Asked Questions (FAQ)
What is CDC RFA GH13-1335?
CDC RFA GH13-1335 is a U.S. Centers for Disease Control and Prevention (CDC) funding opportunity issued as a cooperative agreement under PEPFAR. It is focused on strengthening the South African Department of Health's capacity to deliver high-quality, sustainable clinical care for people living with HIV, particularly those with complicated HIV disease and those needing complex HIV/TB co-treatment and advanced antiretroviral management.
What is the main goal of this cooperative agreement?
The main goal is durable capacity building rather than only direct service delivery. The opportunity emphasizes strengthening clinical and program management systems, improving quality of care for complex cases, reinforcing laboratory and surveillance infrastructure, and ensuring advanced HIV and HIV/TB treatment services can be delivered reliably and at scale over time.
Who is the primary country partner for this work?
The work is designed to strengthen the capacity of the South African Department of Health and is expected to be carried out in close collaboration with the South African government and other partners.
Is this funding opportunity part of PEPFAR?
Yes. The opportunity is described as a CDC cooperative agreement under PEPFAR and aligns with a broader partnership framework coordinated under the U.S. Global AIDS Coordinator.
What types of patients and clinical needs are emphasized?
A central emphasis is on people living with HIV who have complicated HIV disease and those requiring complex HIV/TB co-treatment and advanced antiretroviral management. In particular, the opportunity highlights improving systems and clinical expertise for managing second-line and third-line antiretroviral therapy (ART) and other advanced HIV treatment needs.
What are the four broad priority areas described in the announcement?
The announcement frames the work around four broad priority areas:
- Primary prevention of HIV infection (including confidential counseling and testing linked to evidence-based behavior change interventions, and strengthening prevention of mother-to-child transmission).
- Improving care and treatment across HIV/AIDS, sexually transmitted infections (STIs), and opportunistic infections (including upgraded STI management, expanded laboratory diagnostic capacity, and improved detection and treatment of opportunistic infections and other conditions that worsen outcomes for people with HIV, with tuberculosis highlighted as a key co-morbidity; also includes support for initiating and improving ART programs and sustaining clinical systems).
- Building national capacity to collect, analyze, and use surveillance and program data (including expansion of HIV/STI/TB surveillance and stronger laboratory support for surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety).
- Developing, validating, and evaluating public health programs so prevention and treatment interventions for HIV, TB, and opportunistic infections can be better targeted and continuously improved based on evidence.
How does this opportunity address HIV prevention?
It includes a priority area focused on primary prevention of HIV infection, including expansion of confidential counseling and testing that is connected to evidence-based behavior change interventions, and strengthening efforts to prevent mother-to-child transmission.
How does the opportunity address TB and HIV/TB co-infection?
Tuberculosis is highlighted as a key co-morbidity. The opportunity includes improving detection and treatment of opportunistic infections and other conditions that worsen outcomes for people with HIV, with TB specifically called out, and it emphasizes complex HIV/TB co-treatment as part of advanced clinical management needs.
What role do laboratories play in the proposed work?
Laboratory strengthening appears in multiple priority areas, including expanding laboratory diagnostic capacity for care and treatment, and providing stronger laboratory support for surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety.
What does the announcement say about surveillance and data use?
One priority area is building national capacity to collect, analyze, and use surveillance and program data to manage HIV/AIDS programs more effectively. This includes expanding HIV/STI/TB surveillance and strengthening laboratory support for surveillance-related functions and monitoring.
What is meant by "developing, validating, and evaluating" public health programs?
The opportunity describes a priority area that focuses on improving how public health programs are designed and assessed so that prevention and treatment interventions for HIV, TB, and opportunistic infections can be targeted more effectively and continuously improved using evidence.
What is the funding instrument for this opportunity?
The funding instrument is a cooperative agreement.
What does "cooperative agreement" imply for the working relationship with CDC?
It implies a collaborative model in which CDC is substantially involved in guiding and supporting implementation. Applicants are expected to work closely with the South African government and other partners within this cooperative agreement framework.
What is the activity category and CFDA number?
The activity category is health, and the CFDA number listed is 93.067 (Global AIDS).
When was the opportunity posted and what were the key dates?
The opportunity was posted on February 26, 2013. The original and final closing date was April 15, 2013. The archive date was May 15, 2013.
How many awards did CDC anticipate making?
CDC anticipated making 3 awards.
What was the estimated total funding amount?
The estimated total funding amount was $50,000,000.
What were the award ceiling and award floor?
The award ceiling was listed as $5,000,000. The award floor was listed as $0.
Was cost sharing or matching required?
No. The announcement stated there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was broad and included U.S. and non-U.S. entities across nonprofit and for-profit sectors, universities and colleges, research institutions, hospitals, community- and faith-based organizations, tribal governments and tribally designated organizations, tribal epidemiology centers, and state and local governments (including U.S. territories and freely associated states).
Could an agent of a state or local government apply?
Yes. The announcement allowed applications from bona fide agents of state or local governments, provided they submitted a legally binding agreement documenting that status.
Where does this opportunity fit within CDC's broader approach?
The announcement describes it as consistent with CDC's typical approach of concentrating support in a small number of major areas per country and tailoring technical assistance to host-country priorities, with alignment to South Africa's national strategic plans.
Is the opportunity mainly for direct clinical service delivery?
The overall intent is described as going beyond direct service delivery, emphasizing sustainable capacity building: stronger systems, better clinical expertise for complex cases, improved quality of care, and reinforced laboratory and surveillance infrastructure.
Who is listed as a point of contact for access issues or administrative support?
The CDC Procurement and Grants Office Technical Information Management Section (TIMS) was listed as the point of contact. The phone number provided was 770-488-2700 and the email address was pgotim@cdc.gov.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Evaluating Thin Film Nanocomposite Membranes to Treat Brackish Waters through Reverse Osmosis
Previous opportunity: Strengthening strategic information, program implementation and capacity building in order to reduce morbidity and mortality in the Republic of South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH13 1335
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH13 1335) also looked into and applied for these:
| Funding Opportunity |
|---|
| Comprehensive HIV TB Prevention, Care and Treatment Services and Systems Strengthening, In Facilities of South Africas Department of Correctional Services (DCS) under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1336 Funding Number: CDC RFA GH13 1336 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
| Building Capacity of the Vietnam Health System through Provision of HIV/AIDS Clinical Care Mentorship and Technical Assistance under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1363 Funding Number: CDC RFA GH13 1363 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Sustaining Influenza Surveillance Networks and Response to Seasonal and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 1304 Funding Number: CDC RFA IP13 1304 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Service Area Competition Additional Area (SAC AA) Baxley, GA and Brooklyn, NY Apply for HRSA 13 271 Funding Number: HRSA 13 271 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Support and Implement Behavioral Change Communication to Increase Uptake of Highly Effective Prevention Services and Behaviors in Selected Urban and Rural Populations in the Southern and Western Provinces of the Republic of Zambia under the President Apply for CDC RFA GH13 1351 Funding Number: CDC RFA GH13 1351 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD PhD Programs (F31) Apply for PAR 13 127 Funding Number: PAR 13 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1321 Funding Number: CDC RFA GH13 1321 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
| Provision of Comprehensive Care and Treatment Programs by Local Indigenous Entities in the United Republic of Tanzania under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1322 Funding Number: CDC RFA GH13 1322 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Strengthening Human Resources for Health through Public Health Training Improvements at the Muhimbili University of Health and Allied Sciences (MUHAS), School of Public Health and Social Sciences (SPHSS) in the United Republic of Tanzania under PEPFA Apply for CDC RFA GH13 1323 Funding Number: CDC RFA GH13 1323 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Technical Assistance for Strengthening of Blood Transfusion Services and Increasing Access to Safe Blood in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1360 Funding Number: CDC RFA GH13 1360 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Supporting the implementation and capacity building of HIV/AIDS prevention interventions for youth using evidence based approaches in South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1341 Funding Number: CDC RFA GH13 1341 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $6,000,000 |
| Accelerating Progress Against TB in Kenya (APA K) Apply for RFA 615 13 000003 Funding Number: RFA 615 13 000003 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $40,000,000 |
| Genomes to Natural Products (U01) Apply for RFA GM 14 002 Funding Number: RFA GM 14 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,250,000 |
| Investigator Initiated Multi Site Clinical Trials (Collaborative R01) Apply for PAR 13 128 Funding Number: PAR 13 128 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimers Disease Research Centers (P50) Apply for RFA AG 13 019 Funding Number: RFA AG 13 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (SBIR) (R43) Apply for RFA AR 14 005 Funding Number: RFA AR 14 005 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Collaborations for Macromolecular Interactions in Cells (R01) Apply for RFA GM 14 004 Funding Number: RFA GM 14 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research Networks for Macromolecular Interactions in Cells (U54) Apply for RFA GM 14 005 Funding Number: RFA GM 14 005 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIH Directors Biomedical Research Workforce Innovation Award Broadening Experiences in Scientific Training (BEST) (DP7) Apply for RFA RM 12 022 Funding Number: RFA RM 12 022 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NGO Health Service Delivery Program Apply for RFA 442 13 000001 Funding Number: RFA 442 13 000001 Agency: Cambodia USAID Phnom Penh Category: Health Funding Amount: $6,600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH13 1335", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.